Evotec and Novo Nordisk form research alliance in diabetes and obesity

23-Aug-2018 - Evotec AG announced a strategic alliance with Novo Nordisk to discover and develop novel small molecule therapies to treat patients suffering from diabetes and obesity as well as co morbidities such as nonalcoholic steatohepatitis (“NASH”), cardiovascular diseases, and diabetic kidney ...

Enterome and Nestlé Health Science launch new diagnostics company

11-Jul-2017 - ENTEROME SA and Nestlé Health Science, announce the joint creation of Microbiome Diagnostics Partners (MDP). This company will bring together complementary, world-leading platforms and capabilities enabling the discovery and development of innovative diagnostics through to commercialization in ...

Diabetes drug found no better than placebo at treating NAFLD

17-May-2016 - A diabetes medication described in some studies as an effective treatment for nonalcoholic fatty liver disease (NAFLD) works no better than a placebo, report researchers at University of California San Diego School of Medicine, after conducting the first randomized, double-blind, controlled ...

Therapeutic protein targets liver disease

Research identifies a protein that ameliorates liver damage caused by diet induced obesity

12-Jan-2016 - “Non-alcoholic fatty liver disease (NAFLD) is now considered the most common cause of chronic liver disease worldwide and the prevalence has increased beyond 30% in developing countries,” say Jun Wada and colleagues in a recent report. Their research shows that overexpression of the protein Gpnmb ...

Stratification of the severity of Non Alcoholic Fatty Liver disease

10-Dec-2015 - It has been estimated in Europe that approximately 26 % or higher health costs account for NAFLD patients. NAFLD is a typical metabolic disease associated with obesity, insulin resistance and type 2 diabetes. Abnormal fat deposits develop in patients’ livers. In general steatosis is without ...

Fatty liver disease and scarring have strong genetic component

05-Oct-2015 - Researchers at the University of California, San Diego School of Medicine say that hepatic fibrosis, which involves scarring of the liver that can result in dysfunction and, in severe cases, cirrhosis and cancer, may be as much a consequence of genetics as environmental factors. "The most common ...

GE Healthcare and Takeda Join Forces to Develop Therapeutic Drugs to Target Liver Diseases

13-Nov-2014 - GE Healthcare and Takeda Pharmaceutical Company announced that they have entered into an alliance agreement for research and development in the field of hepatic fibrosis, a key factor in the diagnosis and treatment of liver diseases. Liver disease has almost no visible symptoms, and its progress ...

Immune cells in the liver drive fatty liver disease and liver cancer

17-Oct-2014 - Immune cells that migrate to the liver and interact there with liver tissue cells get activated by metabolic stress (e.g. through lipids of a high fat diet) and drive the development of fatty liver disease, non-alcoholic steatohepatitis and liver cancer. Scientists from the Helmholtz Zentrum ...

Raptor Pharmaceutical Corp. Signs Collaborative Research and Development Agreement With NIDDK on Phase 2b Clinical Trial of RP104 in Non-Alcoholic Steatohepatitis

21-Dec-2011 - Raptor Pharmaceutical Corp. announced the signing of a cooperative research and development agreement (CRADA) with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) part of the National Institutes of Health (NIH) to conduct a Phase 2b clinical trial. The clinical trial ...

Raptor Pharmaceutical Licenses Intellectual Property Related to Huntington's Disease

04-Jun-2010 - Raptor Pharmaceutical Corp. announced that the Company has acquired an exclusive worldwide license to intellectual property related to the potential treatment of Huntington's Disease from the Weizmann Institute of Science in Israel and Niigata University in Japan. In addition, Raptor has added ...